For-profit healthcare systems prioritize shareholder returns alongside patient care, and the evidence suggests that tension produces measurably worse outcomes. Patients treated at for-profit hospitals face a 2% higher risk of death compared to those at non-profit hospitals. In a system as large as the United States, that translates to an estimated 14,000 additional deaths per year: people who would have survived if treated at a non-profit facility. The problems extend well beyond hospitals, touching hospice care, drug pricing, and the enormous administrative machinery that sits between patients and the care they need.
Higher Mortality and More Complications
The mortality gap between for-profit and non-profit hospitals has been documented in large-scale analyses published in the BMJ. That 2% relative increase in death risk may sound small in percentage terms, but applied across millions of hospital admissions annually, it produces a body count comparable to a mid-sized natural disaster every single year.
The picture gets sharper when you look at what happens after private equity firms buy hospitals. A study highlighted by the National Institutes of Health found a 25% increase in hospital-acquired conditions following private equity acquisitions. Falls rose 27%. Infections from central lines, a type of IV placed near the heart, jumped nearly 38%. These are complications that stem directly from how a facility is staffed and managed, not from the complexity of the patients walking through the door.
One detail in that research is particularly telling. Overall mortality at private equity-owned hospitals appeared to drop slightly, by about 0.1%, after acquisition. But the same hospitals became significantly more likely to transfer their sickest patients to other facilities mid-stay. When the patients most likely to die are shipped elsewhere before they can die on your watch, mortality numbers look better on paper without any actual improvement in care. The complications data, harder to game through transfers, tells the real story.
Staffing Cuts Drive the Problem
For-profit healthcare entities consistently operate with lower staff-to-patient ratios than their non-profit counterparts. In hospice care, research published in JAMA Internal Medicine found that for-profit hospices provide a narrower range of services to patients and families, offer less comprehensive bereavement support, and maintain fewer staff per patient. For-profit hospices also had a higher disenrollment rate: 10% of their patients left or were discharged before death, compared to 6% at non-profits. That gap suggests patients or families are more frequently dissatisfied with the care they’re receiving, or that for-profit hospices are more willing to drop patients whose care becomes expensive.
For-profit hospices were also more than three times as likely to exceed Medicare’s annual spending cap, meaning they billed Medicare at rates far above what the program considers appropriate for the number of patients served. Twenty-two percent of for-profit hospices exceeded that cap at least once over a five-year period, compared to just 4% of non-profits. The combination of higher billing and lower staffing is a clear indicator of where the money goes: not back into patient care.
The Administrative Cost Problem
The United States spends vastly more on healthcare administration than comparable countries, and for-profit incentives are a major driver. The Commonwealth Fund estimates that higher administrative costs tied to health insurance, including eligibility verification, coding, claim submission, and rework, account for roughly 15% of excess U.S. healthcare spending. The administrative burden placed on providers themselves, covering general administration, human resources, and quality reporting, adds another 15%. Together, administrative overhead represents about 30% of the spending gap between the U.S. and peer nations.
In dollar terms, a 2021 McKinsey analysis estimated hospital administrative costs at $250 billion and clinical services administrative costs at $205 billion. The Commonwealth Fund calculated that the U.S. could save approximately $276 billion annually, about 6.5% of total national health expenditures, if administrative spending were brought in line with other high-income countries. That money doesn’t treat anyone. It pays for the complex infrastructure of billing, prior authorizations, claims disputes, and coverage determinations that a fragmented, profit-driven system requires.
How Drug Middlemen Inflate Prices
Pharmacy Benefit Managers, known as PBMs, illustrate how for-profit intermediaries can distort an entire market. The three largest, Express Scripts, CVS Caremark, and OptumRx, sit between drug manufacturers, insurance companies, and pharmacies. They claim to negotiate lower drug prices. In practice, their profit model often pushes costs higher.
PBMs make money through several mechanisms that are largely invisible to patients. In spread pricing, a PBM reimburses a pharmacy one amount for a drug, say $30, while charging the insurance plan a higher amount, perhaps $45, and pockets the $15 difference. They also collect rebates from drug manufacturers in exchange for favorable placement on a plan’s formulary, the list of covered drugs. A manufacturer whose drug gets “preferred” status on a formulary gains enormous market share, so companies compete by offering larger rebates. PBMs are not required to publicly disclose how much of those rebates they keep versus how much they pass along to insurers or patients. The lack of transparency makes it nearly impossible to know how much of the negotiated savings actually reaches the people paying for prescriptions.
The result is a system where PBMs can be financially incentivized to favor higher-priced drugs, since larger rebates mean larger retained profits. They ultimately control which drugs patients can access and afford through tiered copayment structures. A drug that might cost less at the pharmacy counter could be placed on a higher, more expensive tier simply because a competing drug offered the PBM a better rebate deal.
Where For-Profit Hospice Spending Goes
Hospice care offers one of the clearest windows into how profit motive reshapes healthcare delivery. For-profit hospices serve a significantly larger share of their patients in nursing homes (30% vs. 25% at non-profits) and assisted living facilities (12% vs. 8%), while serving fewer patients at home (59% vs. 64%) and far fewer in dedicated inpatient hospice units (2% vs. 4%). Nursing home and assisted living patients tend to require less intensive, less costly care from the hospice provider, since the residential facility handles much of the day-to-day work. This patient mix allows for-profit hospices to collect Medicare hospice payments while spending less on direct services.
For-profit hospices were also significantly less likely to provide charity care, to serve as training sites for medical professionals (55% vs. 82% of non-profits), or to conduct research. These community benefit activities cost money and don’t generate revenue, so their absence in the for-profit sector follows a predictable logic. The operational model is streamlined around the patients and services that produce the best margin, not around the broadest community need.
Medical Debt and Collections
One area where the for-profit vs. non-profit distinction gets murkier is medical debt collection. Research published in JAMA analyzing Virginia court records found that hospitals sued patients roughly 20,000 times in 2017 and garnished wages more than 9,000 times. Counterintuitively, non-profit hospitals were more aggressive: 43% of non-profits garnished patient wages compared to 33% of for-profits and just 6% of government-owned hospitals. Four non-profit hospitals alone accounted for more than half of all hospital lawsuits in the state that year.
This finding doesn’t exonerate for-profit healthcare so much as it reveals how deeply profit-driven behavior has permeated the entire system. Non-profit hospitals still generate revenue, pay executives competitive salaries, and face financial pressures that can push them toward aggressive collection. The label “non-profit” describes a tax status, not necessarily a philosophy of care. Still, the structural incentives differ. For-profit systems are legally obligated to maximize returns for shareholders, creating a permanent tension with the goal of providing affordable, accessible care. Non-profit systems that behave this way are failing their mission. For-profit systems that behave this way are fulfilling theirs.